论文部分内容阅读
目的:探讨前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床疗效。方法:选取2015年3月至2016年3月我院收治的78例糖尿病肾病蛋白尿患者作为研究对象,按照入院的先后顺序平均分成观察组和对照组,每组各39例,两组患者都积极进行常规的治疗,在此基础上,对照组患者给予前列地尔治疗,观察组在对照组的基础上增加贝那普利进行治疗,观察两组治疗的效果。结果:经过不同的治疗之后,观察组患者治疗的临床效果明显优于对照组P<0.05,有统计学意义。另外,两组患者都没有发生严重的不良反应。结论:在常规治疗的基础上,对糖尿病肾病患者采用前列地尔联合贝那普利进行治疗可以显著地提高治疗的效果,值得在临床上推广和应用。
Objective: To investigate the clinical efficacy of alprostadil combined with benazepril in the treatment of diabetic nephropathy proteinuria. Methods: From March 2015 to March 2016, 78 patients with diabetic nephropathy and proteinuria admitted to our hospital were selected as the research objects, divided into observation group and control group according to the order of admission, with 39 cases in each group. Both groups had Active routine treatment, on this basis, the control group of patients given alprostadil treatment, the observation group in the control group based on the increase of benazepril treatment, the effect of the two groups were observed. Results: After different treatments, the clinical effect of treatment in observation group was significantly better than that in control group (P <0.05), with statistical significance. In addition, no serious adverse reactions occurred in both groups. Conclusion: On the basis of routine treatment, the treatment of patients with diabetic nephropathy with alprostadil plus benazepril can significantly improve the therapeutic effect, which is worthy of clinical application and promotion.